By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Cardiovascular Diseases and Conditions. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "Intravenous prostacyclin is approved for treating pulmonary arterial hypertension (PAH), but it has a short half-life and must be delivered systemically via an indwelling intravenous catheter. We hypothesize that localized jugular vein delivery of prostacyclin-producing cells may provide sustained therapeutic effects without the limitations of systemic delivery."
Our news journalists obtained a quote from the research from the University of Houston, "We generated a vector expressing a human cyclooxygenase isoform 1 and prostacyclin synthase fusion protein that produces prostacyclin from arachidonic acid. Endothelial-like progenitor cells (ELPCs) were transfected with the cyclooxygenase isoform 1-prostacyclin synthase plasmid and labeled with lentivirus expressing nuclear-localized red fluorescent protein (nuRFP). The engineered ELPCs (expressing cyclooxygenase isoform 1-prostacyclin synthase and nuRFP) were tested in rats with monocrotaline (MCT)-induced PAH. In PAH prevention studies, treatment with engineered ELPCs or control ELPCs (expressing nuRFP alone) attenuated MCT-induced right ventricular systolic pressure increase, right ventricular hypertrophy, and pulmonary vessel wall thickening. Engineered ELPCs were more effective than control ELPCs in all variables evaluated. In PAH reversal studies, engineered ELPCs or control ELPCs increased the survival rate of rats with established PAH and decreased right ventricular hypertrophy. Engineered ELPCs provided a survival benefit 2 weeks earlier than did control ELPCs. Microarray-based gene ontology analysis of the right ventricle revealed that a number of MCT-altered genes and neurotransmitter pathways (dopamine, serotonin, and -aminobutyric acid) were restored after ELPC-based prostacyclin gene therapy. Cyclooxygenase isoform 1-prostacyclin synthase-expressing ELPCs reversed MCT-induced PAH."
According to the news editors, the research concluded: "A single jugular vein injection offered survival benefits for at least 4 weeks and may provide a promising option for PAH patients."
For more information on this research see: Endothelial-Like Progenitor Cells Engineered to Produce Prostacyclin Rescue Monocrotaline-Induced Pulmonary Arterial Hypertension and Provide Right Ventricle Benefits. Circulation, 2013;128(9):982-994. Circulation can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA (see also Cardiovascular Diseases and Conditions).
The news correspondents report that additional information may be obtained from L. Zhou, University of Houston, Dept. of Pharmacol & Pharmaceut Sci, Center Expt Therapeut & Pharmacoinformat, Houston, TX, United States. Additional authors for this research include Z.Q. Chen, P. Vanderslice, S.P. So, K.H. Ruan, J.T. Willerson and R.A.F. Dixon.
Keywords for this news article include: Biotechnology, Texas, Houston, Genetics, Synthase, Cardiology, Gene Therapy, Hypertension, Therapeutics, United States, Bioengineering, Cyclooxygenase, Enzymes and Coenzymes, North and Central America, Cardiovascular Diseases and Conditions
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC